You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Details for Patent: 8,927,710

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,927,710 protect, and when does it expire?

Patent 8,927,710 protects XOFLUZA and is included in two NDAs.

This patent has thirty-eight patent family members in seventeen countries.

Summary for Patent: 8,927,710

Title:	Substituted polycyclic carbamoylpyridone derivative
Abstract:	This invention provides compounds having antiviral activities especially inhibiting activity for influenza virus, more preferably provides substituted 3-hydroxy-4-pyridone derivatives having cap-dependent endonuclease inhibitory activity.
Inventor(s):	Akiyama; Toshiyuki (Osaka, JP), Takaya; Kenji (Osaka, JP), Kawai; Makoto (Osaka, JP), Taoda; Yoshiyuki (Osaka, JP), Mikamiyama; Minako (Osaka, JP), Morimoto; Kenji (Osaka, JP), Kageyama; Chika (Osaka, JP), Tomita; Kenji (Osaka, JP), Mikamiyama; Hidenori (Osaka, JP), Suzuki; Naoyuki (Osaka, JP)
Assignee:	Shionogi & Co., Ltd. (Osaka, JP)
Application Number:	13/378,334
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 8,927,710

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genentech Inc	XOFLUZA	baloxavir marboxil	FOR SUSPENSION;ORAL	214410-001	Nov 23, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-001	Oct 24, 2018		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-002	Oct 24, 2018		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-003	Mar 18, 2021		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,927,710

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2009-142166	Jun 15, 2009

PCT Information
PCT Filed	June 14, 2010	PCT Application Number:	PCT/JP2010/060006
PCT Publication Date:	December 23, 2010	PCT Publication Number:	WO2010/147068

International Family Members for US Patent 8,927,710

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	102482219	⤷ Try a Trial
China	102803260	⤷ Try a Trial
China	104151234	⤷ Try a Trial
China	104230795	⤷ Try a Trial
China	105037259	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.